Navigation Links
Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
Date:5/13/2009

OXFORD, England, May 13 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated a phase II clinical development programme for its ragweed allergy therapy. The treatment for allergic rhino-conjunctivitis caused by ragweed pollen is based on Circassia's ToleroMune(R) technology, which has previously achieved successful phase II results in patients with cat allergies. Ragweed is one of the leading causes of allergic reactions in North America, where allergies to its pollen are commonly referred to as 'hay fever'. Circassia is undertaking its latest phase II clinical study in Canada. The double-blind, randomised trial will include 50 patients with confirmed ragweed allergies, and will compare a range of ToleroMune doses with placebo. Unlike most current immunotherapies, which require careful dose escalation over many months and several years of maintenance doses, patients will receive just four standardized doses of ToleroMune treatment over a number of weeks. During the trial investigators will 'challenge' the volunteers with ragweed pollen to assess the impact of the therapy. "Broadening the range of allergies targeted by ToleroMune is an important step for Circassia, underlining our confidence in this breakthrough technology. We have already achieved encouraging results in patients with cat allergies, and are excited to be extending our portfolio of therapies to encompass ragweed allergy," said Steve Harris, Circassia's CEO. "Allergies to ragweed pollen are very common in the US, where they affect over a quarter of the population, and are a growing problem in Europe. We believe that Circassia's new therapy should offer patients important benefits, as ToleroMune has the potential to address the underlying cause of allergy using short, simple courses of treatment that minimize the risk of severe and sometimes life-threatening side effects associated with many exi
'/>"/>

SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
2. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
3. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
4. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
5. Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
6. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
7. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
8. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
9. AFFiRiS Begins Development of a Parkinsons Vaccine
10. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
11. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 Touro University California,s College of ... as the recipient of a $150,000 grant by the ... University to increase research and classroom space on its ... for the study of health sciences, and will help ... and interests of our students," said Shelley Berkley ...
(Date:7/31/2014)... Colo. , July 31, 2014  Cannabis ... in cannabis formulation-based drug development and related consulting, ... production of multiple strains of cannabis and European ... to select the best strains for development of ... the cannabis formulations to market for critical ailments ...
(Date:7/31/2014)... Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company ... conference call on Thursday, August 14, 2014, at 4:30 p.m. ... June 30, 2014. Financial results will be issued in a ... President and CEO James LaFrance will host the ... Date: Thursday, August 14, 2014 Time: 4:30 p.m. Eastern time ...
Breaking Medicine Technology:Touro University California Garners Grant From Long Foundation 2Cannabis Science Initiates Scientific Cultivation Programs to Test Multiple Strains of Cannabis to Obtain Extract Formulations for Clinical Drug Development Targeting Multiple Critical Ailments Starting with Cancer and Neurological Disorders 2Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
...  Eli Lilly and Company (NYSE: LLY ) has ... Women" list for the fourth consecutive year. ... Executives (NAFE), recognizes U.S. companies whose policies and practices encourage ... leadership, demonstrate that commitment. The NAFE Top Companies ...
... NEW YORK, Feb. 6, 2012 Faruqi & ... is investigating potential securities fraud at GenVec, Inc. ... (Logo:  http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... its executives violated federal securities laws by failing ...
Cached Medicine Technology:Lilly Recognized as a Top Company for Executive Women 2Faruqi & Faruqi, LLP Announces Investigation of GenVec, Inc. 2
(Date:7/31/2014)... Fitness on the Go in-home ... which now includes Ottawa along with all major cities ... fitness to clients in Ontario since 2012, but have ... a Canadian owned in-home fitness and personal training company ... and fitter lifestyle. , Fitness on the Go makes ...
(Date:7/31/2014)... Atlanta-based Jvion, a leader in clinical ... lessons in predictive population health analytics as part of ... analytics in healthcare. Ritesh Sharma, Jvion COO, commented, “it ... to understand the impact of and potential within predictive ... and a good portion of it is conflicting or ...
(Date:7/31/2014)... Morristown, NJ (PRWEB) July 31, 2014 ANS ... they receive about the ANS Skull Base Center and what ... the ANS Skull Base Surgery Center ?, Skull base ... reaches the undersurface of the brain, an area historically considered ... way to access these areas was by retracting healthy brain ...
(Date:7/31/2014)... During the July 2014 board meeting of the ... executive director of the Mesothelioma Applied Research Foundation, Mary ... promising clinical trials to choose from than ever before. ... have been reporting increased survival and response rates. Some ... is within the field of immunotherapy. One trial, ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 ProPilates ... with a comprehensive approach to the entire body by ... Pilates studio in South Florida with expectations of continual ... , “We are honored to be a part of ... are proactively seeking a way to improve their health ...
Breaking Medicine News(10 mins):Health News:Fitness on the Go Grows to Ottawa 2Health News:Jvion Releases Top Three Lessons in Predictive Population Health Analytics 2Health News:Jvion Releases Top Three Lessons in Predictive Population Health Analytics 3Health News:Dr. Yaron Moshel of Atlantic NeuroSurgical Specialists (ANS) Discusses Brain Tumor Surgery 2Health News:Dr. Yaron Moshel of Atlantic NeuroSurgical Specialists (ANS) Discusses Brain Tumor Surgery 3Health News:‘More Promising Mesothelioma Clinical Trials than Ever Before,’ Says Expert 2Health News:‘More Promising Mesothelioma Clinical Trials than Ever Before,’ Says Expert 3Health News:Fort Lauderdale Pilates Studio ProPilates Reaches Record Growth with Launch of Spinlates by Pilates Powerhouse and Studio Owner, Tonka Cascais 2Health News:Fort Lauderdale Pilates Studio ProPilates Reaches Record Growth with Launch of Spinlates by Pilates Powerhouse and Studio Owner, Tonka Cascais 3
... , , PITTSBURGH , Jan. 14 ... union, today said that the union is pleased with the progress ... for working families. , (Logo: http://www.newscom.com/cgi-bin/prnh/20080131/DC12982LOGO ) , ... for generations we,ve been fighting for health care for all in ...
... , Jan. 14 Today, attorneys with ... a class action law suit and preliminary injunction on ... Angeles Regional Center (ELARC) for unlawfully terminating the most ... through which the state provides statutorily-required services to people ...
... WASHINGTON , Jan. 14 For those who may ... dealing with the images of the Haiti earthquake aftermath, ... from afar and tips for recovering from disasters on its Web ... lives, the wounded and the destruction of homes and communities as ...
... Jan. 14 As the House and Senate work ... Liability and Access (HCLA) sent a letter to House Speaker ... emphasizing the need to retain and strengthen current medical liability reform ... climate has prevented comprehensive medical liability reform efforts from passing, we ...
... , Jan. 14 Resident Sabrina Ahmed ... slowly to get anything done in her home. To make things easier ... wheelchair through her insurance coverage. Unfortunately, the chair didn,t work, and she ... to call " 7 On Your Side " news (WSPA-TV). WSPA Anchor ...
... may be unfounded, agency says , THURSDAY, Jan. 14 ... on Thursday said it found no good evidence that ... use it to help control chronic obstructive pulmonary disease ... early 2008 by the drug,s maker, "suggesting a small ...
Cached Medicine News:Health News:Health Reform Tax Changes: Good Progress for Workers; Union to Keep Working for Better Bill 2Health News:Class Action Suit Filed to Defend Rights of Children With Autism to Vital, Cost-Saving Treatment 2Health News:Class Action Suit Filed to Defend Rights of Children With Autism to Vital, Cost-Saving Treatment 3Health News:APA Offers Resources on Managing Traumatic Stress in Wake of Haiti Earthquake 2Health News:APA Offers Resources on Managing Traumatic Stress in Wake of Haiti Earthquake 3Health News:Broad Health Coalition Continues to Press for Medical Liability Reform 2Health News:The SCOOTER Store Answers Local News Viewer's Need for Power Chair 2Health News:The SCOOTER Store Answers Local News Viewer's Need for Power Chair 3Health News:Leading COPD Drug Won't Harm Heart: FDA 2Health News:Leading COPD Drug Won't Harm Heart: FDA 3Health News:Leading COPD Drug Won't Harm Heart: FDA 4
Adjustable Velcro© closures at crown and behind the neck distinguish this immediate post-op face and chin garment for maximum support and compression....
Facial Wrap...
Very compressive support for submental liposuction...
Ideal for autoplasty and liposuction of chin and cheeks...
Medicine Products: